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Background: Previous investigations in newborn lambs determined that adenovirus-mediated expression of
antigen to a localized region of the gut induced antigen-specific mucosal and systemic immunity. These
experiments were limited in that the localized region of the gut to which antigen was introduced was sterile and
the influence of colostrum on the antigen was not assessed but they do suggest that mucosal vaccines may be an
effective vaccination strategy to protect neonatal lambs. We propose that persistent oral antigen exposure
introduced in extreme early life can induce immunity in lambs, despite the presence of commensal bacteria and
colostrum.
Results: To test this hypothesis, conventionally raised newborn lambs (n = 4 per group) were gavaged with
ovalbumin (OVA) starting the day after birth for either a single day (2.27 g), every day for 3 days (0.23 g/day), or
every day for 3 days then every second day until nine days of age (0.023 g/day). Lambs gavaged with OVA for 3 to
9 days developed significant serum anti-OVA IgG titres (p < 0.05), but not IgA titres, relative to control lambs (n = 4)
after 3 and 4 weeks. At 4 weeks of age, lambs were immunized with OVA in Incomplete Freund’s Adjuvant via
intraperitoneal (i.p.) injection then lambs were euthanized at 7 weeks. Serum anti-OVA IgG titres were further
augmented after i.p. immunization indicating immunity persisted and tolerance was not induced. Serum IgA titres
remained low regardless of treatment. It is known that i.p. priming of sheep with antigen in Freund’s complete
adjuvant leads to an enhanced number of IgA and IgG antibody containing cells in the respiratory mucosa
(Immunology 53(2):375–384, 1984). Lambs gavaged with a single bolus of 2.27 g OVA prior to i.p. immunization
showed very low titres of anti-OVA IgA in the lung lavage. These data suggest that a single, high dose exposure to
OVA can promote tolerance which impacts response to systemic vaccination in later life. Lambs gavaged with
0.023 g OVA for 9 days (Group C) generated significant anti-OVA IgA titres in lung (p < 0.001) compared to negative
control lambs but no additive effect was observed compared to parenteral control lambs. When splenocytes were
re-stimulated with OVA ex vivo, all groups failed to show increased lymphocyte proliferation or interferon (IFN)-γ
production relative to the parenteral control group.
Conclusions: In agreement with our hypothesis, persistent low dose antigen exposure primes humoral antibody
production in serum in conventionally raised newborn lambs. In contrast, a single high dose bolus of antigen
triggered oral tolerance which negatively impacted the quality and magnitude of the immune response to i.p.
immunization in later life. These tangential responses are important as they indicate that the dose and/or repeated
oral exposure to antigen, such as that which may be found in the neonate’s environment, may promote immunity
or alternatively it may negatively impact responses to parenteral vaccination.
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In the neonatal period, lambs are highly susceptible to
infectious disease [1]. Maternal antibodies from colos-
trum protect lambs from diseases but passive immunity
begins to wane markedly in the first few months after
birth, leaving the neonate susceptible to disease [2]. Suc-
cessful neonatal vaccination would be an efficacious and
cost-effective way to protect lambs from disease during
the perinatal periods but this is largely not practised due
to the limited success reported for vaccination using
parenteral vaccination methods [3-5]. New approaches
to effectively vaccinate newborns so they produce their
own immune responses when passive immunity wanes
are highly sought.
Oral tolerance is a suppressive mechanism designed to
prevent the host immune system from overreacting to
innocuous antigens [6]. Once oral tolerance is induced,
it is sufficiently robust that subsequent exposure to that
antigen, even via a systemic route, suppresses immunity
[7,8].
Previously, it was assumed that the neonatal immune
system was too immature to mount an effective immune
response to vaccines [9,10]. Numerous studies in rumi-
nants have confirmed that fetal lambs can mount an ef-
fective immune response to antigens [11-14] Despite
success in fetal lambs, several reports showed that new-
born ruminants respond poorly to vaccination, possibly
due to interference from passively acquired maternal
antibodies [3-5]. In contrast, others report that, depend-
ing on the dose of the antigen, the type of adjuvant used,
and the type of antigen-presenting cell targeted, neo-
nates can mount an effective immune responses [15].
Mutwiri et al. (2001) determined that the gut-associated
lymphoid tissues (GALT) of newborn lambs was im-
mune competent [15]. Further, they used an intestinal
‘loop’ model to facilitate the localization of human
adenovirus coding for TgD, a bovine herpes virus anti-
gen, to a single jejunal Peyer’s Patch (PP) [15]. They sug-
gested that the adenovirus would produce a consistent
supply of TgD to the jejunal PP and, indeed, the majority
of enterically-immunized lambs responded with strong
mucosal and systemic immunity [15]. However, they ac-
knowledge that the intestinal ‘loops’ were not in direct
contact with colostrum which may contain antibodies or
non-specific inhibitors that could potentially inactivate
the adenovirus vector or otherwise interfere with a vac-
cine. We hypothesized than if neonatal lambs responded
with immunity after enteric immunization with a con-
sistent dose of antigen (delivered by adenovirus), they
should respond to persistent oral antigen immunization
even in the presence of commensal bacteria and colos-
trum. To test this hypothesis, conventionally reared neo-
natal lambs were gavaged with 2.27 g – 0.023 g
ovalbumin (as an experimental antigen) as a single bolusor up to 6 times over a 9 day period starting the day
after birth. Systemic and mucosal immune responses
were assessed using a variety of assays to determine
humoral and cell-mediated immunity.
Results
Serum anti-OVA IgG titres induced in newborn lambs in
response to oral gavage is sensitive to dose and
persistence of antigen exposure
Lambs were gavaged with OVA at day 1 (2.27 g OVA;
Group A), on day 1, 2 and 3 after birth (0.23 g OVA/
day; Group B) and for the first 3 consecutive days after
birth as well as day 5, day 7 and day 9 (0.023 g OVA/
day; Group C) as detailed in Figure 1A. Lambs were bled
on their day of birth and at 4 weeks and 7 weeks of age.
Lambs had unrestricted access to maternal colostrum
and were colonized by commensal bacteria. All lambs
were i.p.-injected with 10 mg OVA plus Incomplete
Freund’s Adjuvant (IFA) at 4 weeks of age, and eutha-
nized at 7 weeks of age. Bronchoalveolar lavages (BALs)
and spleens were collected at time of death. We used
enzyme-linked immunosorbant assays (ELISAs) to
evaluate anti-OVA IgG and IgA tires in blood sera and
respiratory mucosa. The overall kinetics of the OVA-
specific immune response as measured by serum IgG
are depicted in Figure 1B and the data shows that there
was a significant difference in serum anti-OVA IgG titres
between the groups at 4 weeks of age. When the IgG ti-
tres were compared for each group relative to their
serum titres at day 1, we observed that after 4 weeks
there was a significant induction of anti-OVA IgG in the
lambs gavaged for up to 9 days with 0.023 g OVA
(Group C; p < 0.05, Figure 1C). Further, this group of
lambs (Group C) showed significant induction of anti-
OVA IgG titres after 4 weeks (p < 0.05, Figure 1C) rela-
tive to the parenteral control group (note this group had
only received saline up to this point and can be regarded
as a negative control group.) These data indicate that
despite being conventionally reared (i.e. with normal
commensal flora and with access to colostrum), lambs
orally vaccinated for 9 days with 0.023 g OVA alone
showed significant induction of anti-OVA IgG in serum.
Oral administration of 2.27 g OVA the day after birth
(Group A) or 0.23 g OVA daily for 3 days after birth
(Group B) did not promote significant induction of
serum anti-OVA IgG titres which suggest that whether
lambs respond to oral antigen with immunity or not is
dependent upon dose or persistence of exposure.
After 7 weeks (which was 3 weeks after i.p.
immunization), there was a trend towards increased
anti-OVA IgG in all groups, with Group C and the par-
enteral control group showing the highest median values
(Figure 1D). The group of lambs gavaged for 9 days with
0.023 g OVA (Group C) had approximately 2 fold higher
Figure 1 OVA-specific humoral immune responses in serum from newborn lambs gavaged with OVA then i.p. immunized with OVA at
4 weeks of age. (A) Lambs (n = 4/group) were gavaged with OVA at day 1 (2.27 g OVA; Group A), on day 1, 2 and 3 after birth (0.23 g OVA/day;
Group B) and for the first 3 consecutive days after birth as well as day 5, day 7 and day 9 (0.023 g OVA/day; Group C). All groups including the
parenteral control group were i.p. immunized at 4 weeks of age with OVA in IFA. At 7 weeks of age, lambs were sacrificed, and spleens and lung
lavages were harvested. Blood was obtained after 3 weeks, 4 weeks and at time of death. Kinetics of the anti-OVA serum IgG production are
shown in (B). OVA-specific serum IgG titres were measured 4 weeks (C) after birth, as well as 3 weeks post i.p. immunization (D). Kinetics of the
anti-OVA serum IgA production are shown in (E). In (C and D) each data point represents an individual animal and median values are indicated
by horizontal lines. In (B and E), data are represented as median from each group. *p < 0.05.
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the titres observed at 4 weeks of age (Figure 1C). Be-
cause it was clear from Figure 1C that oral exposure of
lambs from Group C showed significant induction of
serum anti-OVA IgG, this further 2 fold increase in
serum IgG after 7 weeks indicates that even after re-
exposure to OVA by a systemic route, immunity, not tol-
erance, persisted. Lambs gavaged for 3 days (Group B)
showed significant induction of anti-OVA IgG relative to
titres from day 1 (p < 0.05, Figure 1D) but because lambs
were i.p.-immunized at 4 weeks of age, it is not clear if
serum anti-OVA IgG titres quantified after 7 weeks indi-
cate induction of mucosal immunity from oral OVA ex-
posure or systemic immunity from i.p. administered
OVA. Lambs gavage with a single bolus of 2.27 g OVA
(Group A) showed a trend towards decreased antibody
production relative to the parenteral control group after
7 weeks but the difference was not statistically signifi-
cant (Figure 1D). These data suggest that a single high
dose bolus of antigen may promote immune tolerance.
Together these results indicate that 9 day oral exposure
to low doses of antigen triggers serum humoral immun-
ity, not oral tolerance. In contrast, a single, high doseexposure may induce oral tolerance which negatively im-
pacts parenteral immunization.
When we assessed the anti-OVA IgA titres in serum,
we observed that some lambs across all groups showed
robust anti-OVA IgA in serum at (Day 0). When we in-
vestigated the ewe serum for anti-OVA IgA, it was
present at high levels in the ewes whose lambs showed
high anti-OVA IgA titres (Figure 1E). Regardless of
whether the lambs consumed high or low anti-OVA IgA
titres, all lambs failed to produce significant anti-OVA
IgA serum titres over time (Figure 1E).
Anti-OVA antibodies in respiratory mucosa induced in
newborn lambs in response to oral gavage is sensitive to
dose and persistence of antigen exposure
According to the ‘Common Mucosal Immune System’
theory, antigen-sensitized precursor B and T lympho-
cytes generated at one mucosal site (i.e. such as the gut)
can be detected at anatomically remote and functionally
distinct compartments (such as the respiratory mucosa)
[16-21]. It is known that i.p. priming of sheep with anti-
gen in Freund’s complete adjuvant leads to an enhanced
number of IgA and IgG antibody containing cells in the
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lambs injected with OVA in IFA by the i.p. route alone
would result in significant IgA antibodies in the bron-
choalveolar lavage. We measured anti-OVA antibody ti-
tres in lung washes 3 weeks post i.p. immunization.
Results indicated that 2 of the 4 animals failed to pro-
duce anti-OVA IgA in the respiratory mucosa but the
remaining two animals produced strong anti-OVA IgA
titres (Figure 2A). We wished to establish whether oral
gavage of newborn lambs influenced the mucosal anti-
OVA IgA titres produced by i.p. immunization alone.Figure 2 OVA-specific humoral immune responses in lung
washes from newborn lambs gavaged with OVA then i.p.
immunized with OVA at 4 weeks of age. Lambs (n = 4/group)
were gavaged and i.p. immunized as described in Figure 1A. Control
newborn lambs were not gavaged or immunized with OVA. Lung
lavages were collected 3 weeks post i.p. immunization and OVA-
specific serum IgA (A) and IgG titres (B) were measured. ELISA titres
are expressed as the reciprocal of the highest dilution resulting in a
reading of two standard deviations above the negative control. Each
data point represents an individual animal and median values are
indicated by horizontal lines. *p < 0.05, ***p < 0.001.Lambs gavaged with a single bolus of 2.27 g OVA prior
to i.p. immunization showed very low titres of anti-OVA
IgA in the lung lavage which may indicate induction of
oral tolerance, although it did not meet the criteria of
statistical significance relative to the parenteral control
group. Lambs gavaged with 0.023 g OVA for 9 days
(Group C) generated significant anti-OVA IgA titres in
lung (Figure 2A; p < 0.001) compared to negative control
lambs but no additive effect was observed compared to
parenteral control lambs. Finally, although the anti-OVA
IgA response in respiratory mucosa generated by lambs
gavaged with 0.23 g OVA for 3 days was significant rela-
tive to the negative control group (Group B; p < 0.05),
the response was much less robust compared to the par-
enteral control group. Next we assessed the titres of
anti-OVA IgG in the respiratory mucosa with and with-
out prior oral exposure to OVA. We observed that
lambs gavaged with 0.23 g OVA for 3 days (Group B),
0.023 OVA for 9 days (Group C) and the parenteral con-
trol group generated a trend towards increased anti-
OVA IgG titres in lung washes compared to control
lambs although the data did not meet the criteria set for
statistical significance (Figure 2B, p < 0.065). Lambs
gavaged with a single bolus of 2.27 g OVA prior to i.p.
immunization showed negligible titres of anti-OVA IgG
in the lung lavage which may indicate induction of oral
tolerance. Collectively, these results suggest that prior
oral antigen exposure in newborn lambs may impact the
magnitude of response to i.p. immunization.
Gavage of neonatal lambs with OVA did not further
promote induction of OVA-specific cell-mediated
immunity
Finally, we sought to determine whether lambs orally
gavaged with OVA starting the day after birth developed
cell-mediated immunity. Spleens were excised from each
lamb at 7 weeks of age and splenocytes were
restimulated with OVA or media. Splenocytes did not
show OVA-specific induction of lymphocyte prolifera-
tion or interleukin (IL)-4 cytokine production in any
groups (Figure 3A and data not shown). However,
splenocytes from lambs gavaged with 0.23 g OVA over
3 days (Group B) generated significant antigen-specific
IFN-γ production compared to unstimulated cells
(Figure 3B, p < 0.05). Splenocytes from lambs in Group
C (p < 0.11) also showed a trend towards OVA-specific
IFN-γ production but this data was not statistically sig-
nificant. From the lambs in Group A and the parenteral
control lambs, two had splenocytes which produced
IFN-γ in response to ex vivo antigen-exposure. It is pos-
sible that lambs exposed for the shorter period with the
higher dose (Group A) experienced limited induction of
cellular immunity but not a humoral response. More an-
imals will be needed to establish whether this is indeed
Figure 3 OVA-specific cytokine production by splenocytes from
lambs gavaged with OVA then i.p. immunized with OVA at
4 weeks of age. Lambs (n = 4/group) were gavaged and i.p.
immunized as described in Figure 1A. Lymphocyte proliferation (A)
and IFN-γ (B) production from ex vivo re-stimulated splenocytes was
measured by ELISA 3 weeks post i.p. immunization. Each data point
represents an individual animal and median values are indicated by
horizontal lines. *p < 0.05.
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lambs did not have any additive effect over what was ob-
served in the group immunized via the i.p. route alone.
Discussion
The present investigation showed that both systemic and
mucosal humoral immune responses were induced fol-
lowing oral immunization of conventionally reared new-
born lambs repeatedly exposed to 0.023 g OVA andprimed with OVA in IFA by the i.p. route. Traditionally,
immunization of the very young has been avoided be-
cause it was presumed that the neonatal immune system
was too immature to respond. However, GALT in rumi-
nants displays extensive fetal and neonatal development
and indeed responsiveness to infectious agents [23]. Oral
inoculation of foals with virulent Rhodococcus equi bac-
teria demonstrated accelerated cytotoxic T lymphocyte de-
velopment and IFN-γ production [24]. In sheep, Emery
et al. determined that lambs repeatedly infected with infec-
tious larvae of Haemonchus controtus or Trichostronglyus
colubrifomis starting from the day of birth for 4–6 weeks
showed significant reduction in mean faecal egg count
compared to control lambs [25,26]. Importantly, the cell-
mediated immune responses (i.e. antigen-specific cellular
proliferative response and IFNγ production) by trickle-
immunised lambs was not significantly greater than that in
control animals, which corroborates our CMI response
[25]. Although at least 50% of all vaccinated animals some
induction of IFNγ compared to media controls, the level of
response was very low (Figure 3A) and no proliferative re-
sponse was observed (Figure 3B). Emery et al. also show
that lambs were protected despite no significant increase in
serum antibody production [25].
When they repeated their trial to include lambs re-
peatedly infected with infectious T. colubrifomi larvae,
only animals also immunised i.p. with 50 μg of the re-
combinant T. colubriformis derived protein in the pres-
ence of IFA showed induction of IgG1 and IgG2 isotypes
antibody secreting cells in mesenteric lymph nodes [26].
In contrast, data from our study showed significant in-
duction of OVA-specific serum IgG prior to and post i.p.
immunization (Figure 1A-C) and significant mucosal
IgA but not IgG was induced after i.p. immunization
(Figure 2A, B). Experiments by Mutwiri et al. (2001) de-
termined that consistent exposure of a localized region
of the newborn GALT to antigen was sufficient to pro-
mote mucosal and systemic immunity [15]. Specifically,
they localized adenovirus coding for TgD antigen to a
segment of the newborn gut. They presumed that anti-
gen would be consistently expressed (although the levels
and duration of expression were not assessed [27]).
While their results were intriguing, antigen in this study
was introduced to the gut with several potentially
confounding factors. Because the immunized intestinal
‘loops’ were created in fetal lambs at late gestation and
the ‘loops’ were made to be sterile, the antigen was not
diluted out by the presence of commensal flora. Further,
because the ‘loops’ were removed from the active digest-
ive tract (while still keeping lymphatics, enervation and
blood flow intact), antigen was not influenced by the po-
tentially inhibitory factors present in colostrum and milk
and the peristaltic action of the gut. Regardless, these ex-
periments showed that antigen alone (or at least one
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gion of a sterile gut could promote mucosal and sys-
temic immunity in newborn lambs. Our data expanded
upon this research by establishing that oral antigen alone
could promote immunity in conventionally reared new-
born lambs despite being colonized with commensal
bacteria. Specifically, lambs gavaged with 0.023 g OVA
persistently for 9 days showed induction of anti-OVA
IgG in serum after 4 weeks even without localizing the
antigen to a specific region of the gut. If oral tolerance
to OVA had been induced, re-exposure to the antigen by
intraperitoneal injection should have resulted in a reduc-
tion of serum anti-OVA IgG titres after 7 weeks. Instead,
we observed that the anti-OVA IgG titres increased rela-
tive to what was observed after oral exposure alone
(week 4). In fact, average serum titres from lambs
gavaged with 0.023 g OVA for 9 days (Average = 2.3 ×
10∧ 5+/−1.7 × 10∧ 5 (StDev) were 1.8 fold higher than was
what observed in lambs injected with OVA i.p. without
prior oral exposure (Parenteral control group; Average =
1.3 × 10∧ 5+/−1.2 × 10∧ 5 (StDev)). Therefore, persistent
low dose antigen exposure by the oral route can pro-
mote immunity in lambs. However, our experimental de-
sign is limited in that it is unclear whether the low dose
or duration of exposure (or both) contributed to the im-
mune response. Further studies must be undertaken to
clarify the precise dose and duration of exposure re-
quired for induction of immunity as well as including
direct measurements of mucosal immunity. This know-
ledge will contribute to our understanding of the under-
lying mechanisms by which this vaccination strategy
promotes immunity.
Immunization in the perinatal period should be amen-
able to current animal husbandry practices as large ani-
mals are often segregated from the herd prior to
lambing/calving/farrowing and are accessible to pro-
ducers. Oral gavage (drenching) is routinely performed
by producers without the need for veterinary assistance
and oral administration negates the need for needles
which reduces risk of carcass condemnation in meat-
producing animals. However, we are aware that repeated
oral drenching over a period of days is not likely going
to be embraced by producers unless the results are ro-
bust enough to warrant this approach, which is not the
case with our data. We submit that the results are intri-
guing enough to warrant further study. Future experi-
ments should include larger numbers of lambs per
group to establish how this vaccination strategy affects
an out-bred animal population. We intend to study
whether a single (or at most two) oral gavage(s) are suf-
ficient to promote immunity if the dose is low (i.e.
0.023 g OVA on the day of birth and/or for 2 days after
birth) which is much more likely to be accepted by the
livestock industry should the results prove favourable. Itis known that the gut of newborn ruminants is semi-
permeable for only the first 24–36 hours after birth to
facilitate passive transfer of maternal antibodies from the
colostrum [28]. Dendritic cells (DCs) within the sub-
epithelial dome may present antigens to T cells in the
Peyer’s Patch or isolated lymphoid follicle (ILF) [29-31]
rather than being taken up by tolerogenic mucosal DCs
which sample the intestinal lumen then migrate prefer-
entially to the mesenteric lymph nodes (MLNs) upon
antigen uptake [32]. If induction of oral immunity re-
quires that the antigen traverse the gut wall, it may be
that despite administering OVA for 9 days to lambs in
Group C, only the first 2–3 doses traversed the gut wall
and led to induction of oral immunity. Experiments are
underway to elucidate the kinetics of gut permeability
and the impact this has on the mechanisms of antigen
uptake and where antigen presentation to lymphocytes
occurs (i.e. in the Peyer’s patches, isolated lymphoid fol-
licles, or mesenteric lymph nodes). Should future studies
show that early life oral vaccination consistently pro-
motes oral immunity, it will have important implications
for protecting against infectious diseases in the very
young and it may reduce the number of carriers of
disease-producing organisms within a herd.
In contrast to the immune response induced in neo-
natal lambs gavaged with OVA over a 9 day period im-
mediately after birth, a single high dose exposure to
antigen appeared to promote a trend towards induction
of oral tolerance in lambs. Our results suggest that in-
appropriate induction of oral tolerance to an antigen
may impede the host from generating an immune re-
sponse to this antigen in the future. These results cor-
roborate what was observed by Buddle et al. (2002)
wherein it was observed that already at 6 weeks of age,
calves had been naturally exposed to mycobacterial anti-
gens [33]. As adults, the cattle with pre-existing re-
sponses to environmental mycobacteria were much less
responsive to vaccination than were naïve adult cattle
[33]. Further experiments must be performed to clearly
determine whether in fact, as our data appears to indi-
cate, early-life antigen exposure in lambs also negatively
impacts future response to vaccination. Should this
prove to be the case, it will be critical to establish 1)
whether a parenteral vaccine can be administered to cir-
cumvent or reverse the tolerogenic response, or 2)
whether it is advisable to proactively orally vaccinate ne-
onates prior to environmental exposure to preserve their
ability to promote an immune response to later patho-
gen or vaccine exposure events.
Conclusions
In the present study, we determined that repeated low
dose oral administration of OVA for 9 days of age
starting the day after birth induced priming of the
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higher dose oral exposure in neonatal lambs promoted
what appeared to be a tolerogenic response which nega-
tively impacted the immune response to parenteral vac-
cination in later life. We conclude that neonatal lambs
are receptive to either induction of immunity or oral tol-
erance if exposed to antigen in the period immediately
after birth, depending on the dose and/or kinetics of ex-
posure. These results are intriguing and should be stud-
ied further to establish whether it may be advisable to
proactively orally vaccinate newborn lambs not only to
promote immunity but to ensure that the they can re-
spond appropriately to parenteral vaccines in later life.Methods
Immunization procedure
This work was approved by the University of
Saskatchewan’s Animal Research Ethics Board, and ad-
hered to the Canadian Council on Animal Care guide-
lines for humane animal use. Pregnant Suffolk-cross
ewes were housed at VIDO for at least 3 days prior to
lambing with ad libitum access to standard feed and
water. Ewes were subjected to intramuscular injection
with 3 ml of 5 mg/ml Dexamethasone (Dexocort-5, Raf-
ter, Calgary, AB) at day −1 to promote labour. We
gavaged lambs with a single bolus of 2.27 g OVA, 0.23 g
OVA daily for 3 days, or 0.023 g OVA (Sigma-Aldrich
Canada Ltd, Oakville, ON, Canada) for 3 consecutive
days followed by oral gavage at the same dose at 5 days,
7 days and 9 days (Figure 1A). Lambs were randomly
assigned to treatment groups. A total volume of 60 ml
was administered via gavage using soft Nalgene Tubing
with a monojet catheter tip (Fisher Scientific Ltd.,
Ottawa, ON) gently inserted into the back of the throat.
Although not all lambs were born on the same day, the
timing of gavages and other treatments were maintained
for each according to that described in Figure 1A. At
4 weeks age, lambs were i.p.-injected with 10 mg OVA
plus IFA (Sigma-Aldrich Canada Ltd.). To generate a
parenteral control group, lambs received saline by oral
gavage and they were i.p. immunization with OVA as in-
dicated above. This route was used because it is consid-
ered relevant for stimulating the mucosal tissues [11,34].
Control lambs (see Figure 2) did not undergo any form
of immunization. Sheep were euthanized using 2 ml/
10 lb body weight with Pentobarbital Sodium Injection
(240 mg/ml; Euthanyl, Bimeda-MTC Animal Health
Inc., Cambridge, ON). Sera was obtained after 3 weeks,
after 4 weeks (immediately prior to i.p. immunization)
and at 7 weeks of age. Lung lavages and spleens were
obtained at the end of the trial (7 Weeks; Figure 1A).
Endotoxin levels in OVA was determined to be 8,000 U/
ml using the Limulus Amebocyte Lysate enzymatic assayQCL-1000 (Lonza Group Ltd, Basel, Switzerland)
according to the manufacturer’s instructions.
Serum and lung lavages ELISA
To measure OVA-specific antibody titres, blood sera and
lung lavages was obtained as previously described [35,36].
Immunolon II microtiter plates (Dynex Technology Inc.,
Chantilly, VA, USA) were coated overnight at 4°C with
OVA at 10 μg/ml in carbonate coating buffer (15 mM
Na2CO3, 35 mM NaHCO3, pH 9.6) and 100 μl of antigen
was added to each well. Wells were washed 5 times with
Tris-buffered saline (pH 7.3) containing 0.05% Tween 20
(TBST). Diluted sheep serum samples were added to the
wells at 100 μl/well and incubated overnight at 4°C. Wells
were washed again with TBST and biotinylated rabbit anti-
sheep IgG (KPL, Gaithersburg, MD, USA, #16-23-06, 1/
5000), or rabbit anti-sheep IgA (Bethyl Laboratories,
Montgomery, TX, USA; 1/1,000) (which was biotinylated
in-house using standard techniques) were added to the
wells in a 100 μl volume and incubated for 1 h at room
temperature (RT) where appropriate. Wells were washed
alkaline phosphatase conjugated with streptavidin (Jackson
Laboratories, CA, USA; 1/5,000) was added to each well
followed by incubation for 1 h at RT. Wells were washed 5
times in TBST before di(Tris) p-nitrophenyl phosphate
(PNPP) (Sigma-Aldrich Canada Ltd.) was diluted 1/100 in
PNPP substrate buffer (1 mM of MgCl2, 200 mM of
Tris–HCl, pH 9.8) and 100 μl/well was added to the
wells. The reaction was allowed to develop for 15 min
before absorbance was read as optical density (OD) at
405 nm in a Microplate Reader (Bio-Rad Laboratories,
CA, USA). Results were reported as titres which are
the reciprocal of the highest dilution that gave a posi-
tive OD reading. A positive titre was defined as an OD
reading that was at least two times greater than the
values for a negative sample. All ewes showed negli-
gible anti-OVA IgG in their serum and colostrum
(Figure 1B-D).
Splenocyte cytokine ELISAs
To measure systemic immune responses, splenocytes
were isolated, processed, and cultured in triplicate wells
at a concentration of 6 × 105 cells/well as detailed in
[35] in the presence of 10 μg/mL OVA or media for 18–
20 h. Ovine IFN-γ ELISA kit (MABTECH, Mariemont,
OH, USA) were performed according to manufacturer’s
recommendations. For ovine IL-4, polystyrene microtitre
plates were coated with bovine IL-4 (AbD Serotech,
Raleigh, NC, USA; MCA1820) used at 1 μg/ml in 100 μl
volume with carbonate coating buffer and incubated at
4°C overnight as detailed above. Wells were washed 5
times with Tris buffered saline (pH 7.3) containing
0.05% Tween 20 (TBST). Diluted sheep supernatants
were added to the wells at 100 μl/well and incubated for
Buchanan et al. BMC Veterinary Research 2013, 9:160 Page 8 of 9
http://www.biomedcentral.com/1746-6148/9/1602 h RT. Wells were washed again with TBST and bound
cytokines were detected using 1 μg/ml in 100 μl mouse
anti-bovine antibody (sc-101845, Santa Cruz Biotech,
Santa Cruz, CA, USA.) which was introduced for 1 h at
RT. Wells were washed and alkaline phosphatase conju-
gated goat anti-mouse IgG (KPL, 1/5000) was added to
each well followed by 1 h incubation at RT. Wells were
washed 5 times in TBST and detected as detailed above.
Serially diluted recombinant bovine IL-4 was used as
standards. For each cytokine ELISA, standard curves
were constructed to calculate the cytokine concentra-
tions in the samples. Values were corrected for
background cytokine secretion by subtracting the con-
centrations in the control (medium) wells.Lymphocyte proliferative response assays
Following the procedure outlined in [37], spleens were iso-
lated, processed, and cultured in 96-well flat-bottom plates
(Nalge Nunc International, Naperville, IL, USA) at 3 × 105
cells/well in a final volume of 200 μl culture medium with
triplicate wells containing either medium alone or 10 μg/
ml OVA. Cells were incubated for 72 h followed by the
addition of 0.4 μCi 3H-thymidine (Amersham Pharmacia
Biotech, Baie d’Urfe QC, Canada)/well for another 16 h of
culture. Cells were freeze-thawed and harvested onto
Unifilter plates (Perkin-Elmer, Boston, MA, USA) and
incorporation of 3H-thymidine was measured as counts
per minute (cpm) using a liquid scintillation counter
(Top-Count, Perkin-Elmer).Statistical analysis
The outcome data from this study were not normally
distributed. Therefore, differences among experimental
groups were tested using Kruskal-Wallis analysis and
medians were compared using Dunn’s test. In those in-
stances where repeated measures were made on the
same animals over time, the data for each animal were
summed over the duration of the study and then
Kruskal-Wallis analysis and Dunn’s test were performed
on the sums. Differences were considered significant if
P < 0.05. All statistical analyses and graphing were
formed using GraphPad Prism 5 software (GraphPad
Software, San Diego, CA).Abbreviations
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